Nikko Asset Management Americas Inc. Sells 786,127 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Nikko Asset Management Americas Inc. reduced its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 8.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,908,651 shares of the company's stock after selling 786,127 shares during the quarter. Nikko Asset Management Americas Inc. owned about 2.28% of Recursion Pharmaceuticals worth $60,133,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Signaturefd LLC increased its stake in Recursion Pharmaceuticals by 45.0% in the 4th quarter. Signaturefd LLC now owns 11,769 shares of the company's stock worth $80,000 after acquiring an additional 3,651 shares during the last quarter. Cibc World Markets Corp bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth approximately $157,000. Swiss National Bank raised its stake in Recursion Pharmaceuticals by 36.3% in the fourth quarter. Swiss National Bank now owns 486,700 shares of the company's stock valued at $3,290,000 after purchasing an additional 129,600 shares in the last quarter. Farther Finance Advisors LLC lifted its position in Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares during the last quarter. Finally, HighTower Advisors LLC grew its stake in Recursion Pharmaceuticals by 408.5% in the 4th quarter. HighTower Advisors LLC now owns 122,770 shares of the company's stock worth $830,000 after buying an additional 98,626 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Remove Ads

Analyst Ratings Changes

RXRX has been the subject of a number of research analyst reports. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Finally, KeyCorp dropped their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $8.25.

Recursion Pharmaceuticals Trading Up 3.1 %

Shares of NASDAQ:RXRX traded up $0.20 on Friday, reaching $6.68. 17,924,603 shares of the company traded hands, compared to its average volume of 10,490,157. The stock has a market capitalization of $2.69 billion, a P/E ratio of -4.37 and a beta of 0.85. The business's 50-day simple moving average is $7.47 and its 200 day simple moving average is $7.00. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.60 and a 52 week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the previous year, the business earned ($0.42) earnings per share. Recursion Pharmaceuticals's revenue was down 57.8% compared to the same quarter last year. As a group, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.